Growth & profitability
- Revenue has grown 0.9% per year over the past 5 years.
- Operating margin has expanded, at -12.6% in the latest year.
SNOA Financials Sonoma Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $20M | $3175 | 38.0% | -12.6% | 0.1% | 0.0% | -$4M | — | $2M |
| 2025 | $14M | $3457 | 38.2% | -26.0% | 0.1% | 0.0% | -$168000 | — | $5M |
| 2024 | $13M | $4835 | 37.3% | -36.9% | 0.1% | 0.0% | -$2M | — | $3M |
| 2023 | $13M | -$5M | 33.7% | -34.4% | -64.6% | -31.7% | -$6M | — | $4M |
| 2022 | $13M | -$5M | 31.6% | -46.6% | -58.5% | -27.0% | -$4M | $0 | $7M |
| 2021 | $19M | -$4M | 35.2% | -18.5% | -73.7% | -26.4% | -$4M | $2M | $4M |
| 2020 | $18M | -$3M | 45.3% | -41.2% | -58.8% | -22.7% | -$5M | $481000 | $4M |
| 2019 | $19M | -$12M | 46.8% | -59.3% | -151.8% | -81.7% | -$12M | $334000 | $4M |
| 2018 | — | -$14M | — | — | -93.5% | -74.6% | — | $262000 | $10M |
| 2017 | — | $9M | — | — | 43.3% | 36.4% | — | $172000 | $17M |
| 2016 | — | -$10M | — | — | -100.2% | -73.6% | — | $114000 | $7M |
| 2015 | — | -$8M | — | — | -68.1% | -54.5% | — | $87000 | $6M |
| 2014 | — | $4M | — | — | 31.0% | 18.0% | — | $147000 | $5M |
| 2013 | — | -$5M | — | — | -133.1% | -43.2% | $893000 | $3M | $8M |
| 2012 | — | -$7M | — | — | 844.4% | -93.5% | -$4M | $3M | $3M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $6M | -$330000 | 40.2% | -0.6% | -5.0% | -1.8% | -$651000 | — | $5M |
| Mar '26 | $6M | -$581000 | 39.2% | -6.3% | -18.8% | -4.2% | -$548000 | — | $2M |
| Dec '25 | $4M | -$819000 | 37.9% | -15.6% | -23.9% | -6.0% | -$811000 | — | $3M |
| Sep '25 | $6M | -$534000 | 37.8% | -6.0% | -14.1% | -3.9% | -$645000 | — | $3M |
| Jun '25 | $4M | -$1M | 36.5% | -27.3% | -30.6% | -8.5% | -$2M | — | $4M |
| Mar '25 | $4M | -$776000 | 40.7% | -17.5% | -17.6% | -5.7% | -$142000 | — | $5M |
| Dec '24 | $4M | -$928000 | 35.6% | -28.9% | -19.1% | -6.8% | $563000 | — | $5M |
| Sep '24 | $4M | -$610000 | 38.0% | -23.7% | -11.4% | -4.5% | $328000 | — | $4M |
| Jun '24 | $3M | -$1M | 38.5% | -34.6% | -23.0% | -8.4% | -$917000 | — | $3M |
| Mar '24 | $3M | -$1M | 31.7% | -41.0% | -17.4% | -7.2% | $170000 | — | $3M |
| Dec '23 | $3M | -$866000 | 46.5% | -26.9% | -12.9% | -5.9% | -$1M | — | $2M |
| Sep '23 | $3M | -$1M | 36.3% | -44.2% | -26.1% | -10.9% | -$1M | — | $2M |
| Jun '23 | $3M | -$1M | 35.1% | -36.2% | -19.6% | -8.9% | -$232000 | — | $4M |
| Mar '23 | $3M | -$1M | 28.7% | -38.1% | -16.4% | -8.1% | -$3M | — | $4M |
| Dec '22 | $3M | -$2M | 28.2% | -62.3% | -34.9% | -13.9% | -$379000 | $15000 | $3M |
| Sep '22 | $3M | -$1M | 46.1% | -21.9% | -14.5% | -6.8% | -$2M | $15000 | $3M |
| Jun '22 | $4M | -$887000 | 41.3% | -21.5% | -11.1% | -5.2% | -$2M | $15000 | $6M |
| Mar '22 | $2M | -$3M | 4.2% | -133.2% | -33.9% | -15.6% | -$1M | $0 | $7M |
| Dec '21 | $3M | -$944000 | 41.5% | -33.0% | -8.5% | -4.9% | -$327000 | — | $9M |
| Sep '21 | $4M | -$100000 | 33.1% | -25.7% | -0.9% | -0.5% | -$1M | $0 | $8M |
Valuation over time
How the market has priced SNOA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 156.5× (Apr '24) to 1975.7× (Sep '26).
- The price-to-sales ratio has fallen from 0.3× (Mar '23) to 0.3× (Sep '26).
P/E
P/S
Frequently asked questions
Is SNOA growing its revenue and profit?
Over the past 5 years, Sonoma Pharmaceuticals, Inc.'s revenue has grown 0.9% per year. These are computed facts, not advice.
How much debt does SNOA have?
As of FY2026, Sonoma Pharmaceuticals, Inc. reported — of total debt against $2M of cash.
What is SNOA's profit margin?
In FY2026, gross margin was 38.0%, operating margin -12.6%, and net margin 0.0%.
What is SNOA's P/E ratio?
As of Sep '26, Sonoma Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 1975.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.